“The warmth and spirit of events like these represent the best of what the Penn Medicine community stands for, and it is always gratifying to showcase the unparalleled depth and breadth of expertise from our outstanding faculty,” said Dean J. Larry Jameson, MD, PhD.
Penn Cardiovascular Institute Director Dan Kelly, MD, brings a unique perspective to research with his expertise in diabetic heart disease.
Wilson Szeto, MD, a pioneer in the rapidly evolving field of transcatheter cardiovascular surgery, talked to guests in Naples about new techniques on the horizon.
“Immunotherapy is the ‘overnight success’ that was more than 20 years in the making, and it was early investments from Penn Medicine and our donor community that has helped Philadelphia emerge as the biomedical ‘Cellicon Valley,’” said Robert Vonderheide, MD, DPhil, the John H. Glick, MD Abramson Cancer Center Director’s Professor and director of the Abramson Cancer Center.
“Addiction is one of the most significant and complex problems facing medicine today,” said Caryn Lerman, PhD, the John H. Glick, MD Pro¬fessor in Cancer Research and vice dean for strategic initiatives. “The history and breadth of our expertise means we’re making an impact at the personal and public health level.”
Chief Scientific Officer Jonathan Epstein, MD, led an all-star panel of cancer researchers who expanded on the promise of immunotherapy—and the new early detection and treatment approaches to come.
“Everyone knows that the brain is complicated and that any mental illness, such as addiction, is difficult to cure—so how can we prevent it?” Chair of Neuroscience and David J. Mahoney Professor of Neurological Sciences John Dani, PhD, discussed his work discovering the mo¬lecular basis of nicotine addiction and what forces can shape the brain.
